Veracyte Inc (NASDAQ:VCYT) traded in a range yesterday that spanned from a low of $24.48 to a high of $25.69. Yesterday, the shares fell 1.9%, which took the trading range below the 3-day low of $24.59...
We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...
Veracyte Inc (NASDAQ:VCYT) traded in a range yesterday that spanned from a low of $23.30 to a high of $24.30. Yesterday, the shares gained 4.1%, which took the trading range above the 3-day high of $23.89...
Veracyte, Inc. (Nasdaq: VCYT) today announced that it will release its financial results for the third quarter 2019 and business progress after the close of market on Tuesday, October 22, 2019. Company...
Veracyte, Inc. (Nasdaq: VCYT) today announced that preliminary clinical data for the company's noninvasive nasal swab test - the first of its kind - for early detection of lung cancer will be presented...
Veracyte Inc (NASDAQ:VCYT) traded in a range yesterday that spanned from a low of $23.68 to a high of $24.56. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $24.43...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that it has appointed Karin Eastham as an independent director to its Board of Directors. Ms. Eastham brings more...
Veracyte, Inc. (Nasdaq: VCYT) today announced the publication of new data demonstrating the clinical and analytical validity of its Afirma(R) Xpression Atlas (XA) genomic test, which is used to help guide...
Veracyte, Inc. (Nasdaq: VCYT) today announced the publication of new data that further define the genomic landscape around thyroid cancer. The study findings help characterize the role of specific gene...
Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson, chairman and chief executive officer, will present at the following upcoming investor conferences:
Here are the top 5 stocks in the Biotechnology industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....
Veracyte (VCYT) delivered earnings and revenue surprises of 44.44% and 3.20%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
SOUTH SAN FRANCISCO, Calif. (AP) _ Veracyte Inc. (VCYT) on Tuesday reported a loss of $2.5 million in its second quarter.
Veracyte (VCYT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Veracyte Inc (NASDAQ:VCYT) traded in a range yesterday that spanned from a low of $28.26 to a high of $29.08. Yesterday, the shares fell 3.1%, which took the trading range below the 3-day low of $28.65...
Veracyte, Inc. (Nasdaq: VCYT) today announced that it will release its financial results for the second quarter 2019 after the close of market on Tuesday, July 30, 2019. Company management will host a...
Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, today announced that it has begun making its next-generation Percepta(R) Genomic Sequencing Classifier (GSC) available to physicians,...
Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, announced today that the company has been awarded a Top Workplaces 2019 honor by the Bay Area News Group for the sixth consecutive...
Veracyte (VCYT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Veracyte Inc (NASDAQ:VCYT) traded in a range yesterday that spanned from a low of $24.67 to a high of $24.96. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $24.53...
